Ergothioneine: is the mushroom antioxidant really a longevity vitamin?

What ergothioneine actually is

Ergothioneine is a sulfur-containing amino acid derivative — a small, stable molecule that humans and other animals cannot synthesize. Only certain fungi and bacteria make it. Everything in your body that contains ergothioneine got there from your diet, which in practice means mostly from mushrooms, with smaller amounts riding in through foods grown in soil where ergothioneine-producing microbes live. In that sense it behaves like a vitamin: essential-ish, diet-derived, and impossible to make on your own.

It was discovered in ergot fungus in 1909 and then sat in relative obscurity for most of a century, treated as a biochemical curiosity. What pulled it back into serious science was a reframing by the biochemist Bruce Ames, who in a 2018 perspective proposed a short list of “longevity vitamins” — nutrients that are not acutely essential, so a deficiency will not give you a classic deficiency disease, but whose long-run absence may quietly accelerate aging and disease. Ergothioneine made his list alongside compounds such as taurine.¹ That framing is the entire premise of the modern ergothioneine story, and it is worth holding two things in mind at once: it is a thoughtful hypothesis from a serious scientist, and it is a hypothesis.

The transporter that started the longevity case

Here is the observation that makes ergothioneine genuinely hard to dismiss. In 2005, researchers identified a specific protein — OCTN1, encoded by the gene SLC22A4 — whose job appears to be transporting ergothioneine into cells. It moves ergothioneine far more efficiently than the other substrates it was once thought to handle, to the point that the protein is now often called simply the ergothioneine transporter.²

Think about what that implies. Evolution does not usually build and maintain a dedicated, high-specificity transport system for a molecule the body has no use for. The presence of OCTN1 — and the fact that it is expressed heavily in tissues that take a lot of oxidative punishment, including blood cells, bone marrow, the gut lining, the eyes, and parts of the brain — is the strongest single argument that ergothioneine is doing something physiological rather than just passing through. This is why I grade the “it has a real role” claim MODERATE rather than higher or lower: a dedicated transporter is powerful indirect evidence, but a transporter tells you the body wants the molecule somewhere, not that topping it up changes how long or how well you live.

Your cells built a dedicated machine to pull this molecule out of your food and hold onto it. Nature rarely invests that effort in something inert — which is exactly why the question is so interesting, and not yet answered.

The mechanism: an antioxidant built for the worst neighborhoods

This is the one section where the chemistry belongs. Ergothioneine’s headline function is as an antioxidant, but the more precise framing is cytoprotective — it shields cells from the kinds of damage that pile up over a lifetime. Chemically it scavenges several damaging reactive oxygen and nitrogen species and chelates pro-oxidant metals such as copper, dampening the chain reactions that let oxidative stress spread through a cell.⁷ Unlike many antioxidants, it is remarkably stable at the body’s pH and does not readily become a pro-oxidant itself, which is part of why it can be stockpiled safely.

The detail that ties the mechanism to the transporter is where it ends up. Through OCTN1, ergothioneine is concentrated precisely in the tissues facing the heaviest oxidative load — and within cells it accumulates near the mitochondria, the organelles that generate energy and, as a byproduct, the bulk of a cell’s reactive oxygen species.⁷ An antioxidant that the body actively routes to its most exposed, highest-stress neighborhoods is a more compelling story than one that floats around generically. In cell and animal models this translates into protection against oxidative injury, reduced inflammation, and preserved mitochondrial function.⁷

The honest caveat, the same one that haunts every antioxidant story: a clean mechanism in a dish and in mice is a reason to investigate, not a result you can put on a label. The history of antioxidant supplements is littered with molecules that looked beautiful at the bench and did nothing — or occasionally harm — in large human trials. Ergothioneine has a better mechanistic profile than most, but that history is the reason for restraint.

The epidemiology: low levels, worse outcomes

This is where the case gets its real-world weight, and also where the most important distinction in the whole article lives: association is not causation. Keep that flag up as you read every number below.

The cardiovascular and mortality data are the headline. In a large Swedish prospective cohort drawn from the Malmö Diet and Cancer study, plasma metabolites were measured at baseline and participants were followed for more than two decades. Of all the metabolites examined, ergothioneine was the one most strongly associated with lower disease and death. Higher blood ergothioneine tracked with lower risk of coronary artery disease (about 15% lower per standard-deviation increment), lower cardiovascular mortality (about 21% lower per SD), and lower all-cause mortality.³ That is a striking signal in a well-conducted cohort.

The cognitive data run in parallel. In an elderly cohort attending memory clinics, low plasma ergothioneine predicted poorer baseline cognition and faster decline across memory, executive function, attention, and language — not just a snapshot, but a trajectory.⁴ Other work has shown blood ergothioneine falls with age past about 60, and that people with mild cognitive impairment carry lower levels than matched peers.⁴ And the food-level epidemiology rhymes with all of it: higher mushroom consumption associates with better cognitive performance and lower odds of mild cognitive impairment in several populations, with ergothioneine the most plausible active ingredient.⁷

Read the right-hand column honestly and the pattern is clear. The observational evidence is unusually consistent for a single nutrient — cardiovascular, mortality, and cognitive signals all point the same way. But low ergothioneine could be a marker of an overall healthier diet and lifestyle rather than a cause of better outcomes. People who eat more mushrooms tend to eat more vegetables, and the studies adjust for what they can measure, never for everything. That is the unbreakable ceiling on observational data, and it is why none of these graphs — however clean — can promote ergothioneine from interesting to proven.

The human trials — where the case thins

Everything above describes a molecule the body values and a biomarker that tracks health. The question that actually matters for anyone considering a supplement is different: if you take ergothioneine, do your outcomes improve? Here the evidence drops from compelling to early, and pretending otherwise would be the exact kind of rounding-up this site exists to push back on.

Start with what is solidly established, because it matters: ergothioneine is well absorbed and strongly retained. In the first controlled human study of pure ergothioneine, healthy adults took 5 or 25 mg daily for a week; blood levels rose substantially, urinary loss was low, and the molecule was avidly held in blood cells rather than flushed out — consistent with everything OCTN1 predicts. It was safe and well tolerated, with no signs of toxicity at those doses.⁵ That establishes the pharmacology and the safety floor. It does not establish a benefit — in those healthy subjects, markers of oxidative damage and inflammation did not move much, which the authors read as latent protective potential held in reserve for when the body is actually stressed, not as a measured clinical effect.⁵

The interventional outcome data are thinner still. The most relevant trial to date is a 2024 pilot in people with mild cognitive impairment, which reported that ergothioneine was safe over extended use and showed early hints of delaying cognitive decline.⁶ Read that the way the researchers would want it read: a pilot is designed to test feasibility and safety and to justify a larger trial — it is not powered to prove efficacy, the participant numbers are small, and a hint is a reason to keep going, not a result to act on. There is, as of this writing, no large randomized controlled trial showing that ergothioneine supplementation prevents cardiovascular events, extends lifespan, or halts cognitive decline in humans. That is the single most important sentence in this article, and it is why the supplement-outcome claim grades EMERGING.

Food first: where ergothioneine comes from

Before anyone reaches for a bottle, the most evidence-aligned move is the cheapest one: eat more mushrooms. Mushrooms are by a wide margin the richest dietary source of ergothioneine, and the strongest real-world data we have — the mushroom-intake epidemiology — is about food, not supplements.⁷ Content varies by species, with some specialty mushrooms carrying several times more than common button mushrooms, but essentially all edible mushrooms contribute, and ergothioneine survives cooking well because it is heat-stable. A couple of servings a week is the habit that actually appears in the studies associating mushrooms with better cognitive outcomes.

It is worth being clear about the framing, because this is where supplement marketing tends to leap ahead of the data. The ergothioneine story is, first and foremost, an argument for a dietary pattern that already has independent support — one that overlaps heavily with the broader case for plants, fiber, and whole foods we map across the supplements hub. The isolated supplement is a reasonable thing to study and a defensible thing to take if you understand it as an experiment rather than a proven intervention. What it is not, yet, is a substitute for the food-and-lifestyle base that the epidemiology was actually built on.

Grey areas: association, dose, and who benefits

Several real uncertainties sit underneath any decision to supplement. The first and largest is the one already named: association versus causation. Low ergothioneine may be a passenger on the same train as poor diet, inflammation, and chronic disease rather than the engine. Mendelian and mechanistic work hint at a causal contribution, but the definitive arbiter — randomized trials with hard endpoints — is not in.

The second is dose uncertainty. The human safety work used modest doses of 5 to 25 mg per day; many commercial products are sold at higher amounts, and the dose that might move a clinical outcome — if any does — is genuinely unknown.⁵ More is not established to be better, and the body’s tight regulation through OCTN1 suggests there may be a ceiling on what tissues will take up regardless.

The third is who actually benefits. The biggest signals come from older adults, people with cognitive impairment, and populations with established cardiovascular risk — groups whose baseline ergothioneine is often already low. Whether a healthy 35-year-old who already eats mushrooms gains anything from a supplement is precisely the question the data cannot answer. As a registered dietitian, my read is that the people most likely to have a real deficit are the ones least likely to be reading supplement labels — and the easiest fix for them is also a plate of mushrooms.

Open questions

The gaps are specific and worth naming plainly, because naming them is the most useful thing this article can do. There is no large randomized controlled trial of ergothioneine for any hard outcome — cardiovascular events, mortality, or dementia incidence — in any population. The cognitive pilot needs to be scaled into an adequately powered, longer trial before its hint means anything.⁶ The causal question — whether raising ergothioneine changes risk, or whether it is simply a faithful marker of a healthier life — remains open. The optimal dose, the right target population, and the long-term safety of higher-than-dietary intake over years are all uncharted.⁵ And the deepest question sits underneath all of them: a body that builds a transporter for a molecule clearly values it, but we still do not know whether more of it, delivered as a pill, does anything a good diet does not already do.²

The verdict

Ergothioneine is the most interesting longevity-vitamin candidate I have looked at, and it earns that on the merits: a dedicated transporter that implies the body genuinely wants it, a clean and well-localized antioxidant mechanism, and unusually consistent epidemiology linking low levels to higher mortality, cardiovascular disease, and cognitive decline.¹²³⁴ That is a real case, and a more grounded one than most supplements ever assemble. It is also, almost entirely, a case built from biology and association — not from trials showing that taking it changes what happens to you.

So who is it for? If you are persuaded by the biology, the food version is close to free of downside and aligned with the strongest data we have: eat mushrooms regularly. If you are a researcher-minded person who wants to take the isolated supplement, it is safe at the studied doses and the rationale is more defensible than most — provided you hold it as an experiment, not a settled intervention, and keep the dose near what has actually been tested.⁵ If you are buying it expecting proven life extension or guaranteed cognitive protection, you are paying for a hypothesis the human trials have not yet confirmed. The same line runs through this whole site: a dedicated transporter and twenty years of mortality data are a powerful reason to be curious, and not the same thing as proof. Ergothioneine is a compound to watch closely — and, for now, a reason to put mushrooms on the plate more than a reason to put a capsule in the cabinet.